Healio3d
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
Medscape21d
Rash Induced by Anti-tumor Necrosis Factor Agents in an Adolescent with Crohn's Disease
Within 2 weeks of his 34 th infliximab infusion, the patient presented with oval plaques 1–3 cm long on his skin. The rash had started as a single, pruritic patch on his shoulder a few days before.
The American Journal of Managed Care3d
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
pharmaphorum9y
Actemra a breakthrough for systemic sclerosis, says FDA
Roche's rheumatoid arthritis (RA ... EU last year and approval of a subcutaneous formulation to replace the older infusion helped the drug grow 23 per cent to 1.22 billion Swiss francs, making ...
pharmaphorum6y
Mycenax’s Actemra biosimilar edges closer to approval
Mycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX ... versus-time curve calculated from start of the infusion until infinity (AUC 0-inf). The study’s prespecified bioequivalence ...